A 22 year old driving a motorized scooter died after being struck by a car in Brooklyn, around 2:30 this morning. Elvis Batista-Francisco was driving his scooter through the intersection of Arlington Ave and Hyland place in Brooklyn, New York when he was struck by a dark blue Nissan according to video surveillance footage. The driver fled leaving the young man to die at the scene of the accident.
Read more in CBS News New York
To prevent traffic crashes, the New York Fire Department is considering adding a safety device under the seat of the ambulance driver to analyze in real time the speed, g-force, seat belt use, lights, sirens and other factors. When the driver becomes too aggressive by driving too fast or taking turns too hard the device emits a sound to alert him.
This device is already used by the emergency medical services at Jersey City Medical Center and drivers said they really like it because it helps them to make an appropriate decision in terms of response time while keeping the safety of the crew and other people on the road in mind.
In the US, there are 10,000 ambulance accidents every year.
Some companies recently advertised the Nipple Aspirate Test as a method for breast cancer screening. The Nipple AspirateTest consists of using a breast pump to collect fluid from a woman’s nipple to screen for breast cancer. According the the FDA there is absolutely no clinical evidence to support these claims. So far the mammogram, even though it is uncomfortable for women, is the only way to screen for breast cancer.
The company that is promoting this false advertising is Atossa Genetics. Atossa Genetics was issued a warning by the FDA that their test test was misbranded in that its labeling was false or misleading and asking them to address the violation. Atossa Genetics voluntary recalled the ForeCYTE Breast Health Test from the market in October 2013.
In its advertising Atossa Genetics falsely claimed that the test was “literally a Pap smear for breast cancer.”
Failure to diagnose May-Thurner Syndrome may be medical malpractice that can lead to post-thrombotic syndrome, potentially fatal pulmonary embolism, pulmonary hypertension, and in the worst case paradoxical embolism.
In a recent article published in the current issue of the Journal of the American Academy of Physician Assistants, the author Jaclyn Leitner who practice general medicine in Newark, New Jersey describes the case of a 28 year old female marathon runner who visited her office with groin pain. The author explains how to properly diagnose May-Thurner syndrome and the available treatments.
Toy testing, toy recalls, toy related injuries and toy shopping will be the subject of the first Google+ Hangout hosted by the CSPC. John Massale, A CSPC engineer, will describe the toy testing process and spokeswoman Nikki Fleming will there to answer all your questions.
You can post your questions on Twitter using #AskCPSC hashtag or on CPSC’s G+ Hangout event page.
In a very sad medical malpractice case a 16 year old girl died of brain cancer after none of the 13 doctors who failed to diagnose the brain tumor ordered an MRI. Natasha Simmons had all the symptoms of a brain tumor: headaches, numbness, back pain, vomiting and problems with her eyesight. She visited 13 doctors over a one year period but none of them ordered an MRI. An ER doctor refused a scan and said they were reserved for life and death situations. 11 months later, an MRI was finally done but it was too late. Natasha Simmons was diagnosed with a cancerous brain tumor and died 8 days later.
Read more in the Huffington Post
Elisa Toro is the third person to die in a car accident at the exit of the Queensboro bridge in New York. Despite traffic modifications by the DOT to slow down traffic, the car of the 10 year veteran police officer ended up sideways against one of the store fronts at the bottom of the ramp. The police officer who wasn’t wearing a seat belt was killed in the accident . The Queensboro ramp is a notoriously dangerous location. Two people previously died in car accidents at that same location.
Read more in the New York Times
Some defective Personal Emergency Reporting System (PERS) Transmitters are being recalled by Linear because the battery clips in the transmitters can corrode causing the transmitters to operate intermittently or not at all, without generating a warning.
The recalled Linear PERS transmitters allow users to push a button on the transmitter to summon assistance. Models recalled are:
22,483 potentially defective motorcycles are being recalled by Harley Davidson. These motorcycles may have a defective clutch system that may prevent the clutch from disengaging. Harley says if the clutch does not disengage, the rider may have difficulty slowing or stopping the motorcycle, increasing the risk of a motorcycle accident.
Read more in Ultimate Motorcycling
Until recently when a patient with prostate cancer was developing resistance to drugs that block testosterone, the hormone that fuels the cancer growth, his urologist would refer him to an oncologist who would start chemotherapy. The situation recently changed with the arrival on the market of new drugs such as sipuleucel-T, radium 223, enzalutamide, abiraterone, and cabazitaxel. These new drugs target so-called “castrate-resistant” patients and can be prescribed by either the urologist or the oncologist.
As of Today there is a lot of confusion about these new drugs. Urologists and oncologists are not clear on whether patients should be treated similarly or which drug should be used and in what order to be the most effective. The lack of communication between specialists as well as the financial incentive in keeping a patient as long as possible may be detrimental to the patient and may lead to medical malpractice.
In an article published Today in the Journal Urologic Oncology, urologist Ralph de Vere White and medical oncologist Primo Lara, Jr. of the UC Davis Comprehensive Cancer Center provide an in depth look at the situation and demonstrate that better guidelines and coordination between specialists are necessary to deliver cost effective and efficient care to patients with castrate-resistant prostate cancer (CRPC).
New York Personal Injury Attorneys Blog